Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Information is lacking regarding real-world testing patterns...

Full description

Bibliographic Details
Main Authors: Yasushi Yatabe, MD, PhD, Yasumasa Yoshiki, MPH, Koichi Matsumura, PhD, Kanae Togo, MSc, Hironori Kikkawa, PhD, Laura Iadeluca, PhD, MPH, Benjamin Li, PhD, Kazuto Nishio, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
Companion diagnostics
Biomarker testing
Time to treatment
Real-world data in Japan
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301879

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301879

Similar Items